NCT01202877 - PKC412 and 5-Azacytidine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Leukemia

Interventions

DRUG

5-azacytidine

Starting dose: 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle.

DRUG

PKC412

Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston